Treace Medical Concepts, Inc. revised earnings guidance for the full-year 2024. The company now expected full-year 2024 revenue of $201 million to $211 million, representing growth of 7% to 13%, compared to full-year 2023. This compares to previous guidance of $220 million to $225 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.65 USD | +0.15% |
|
+11.95% | -47.84% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.84% | 412M | |
+75.69% | 12.57B | |
-28.45% | 6.98B | |
+7.45% | 6.69B | |
+8.73% | 5.18B | |
-19.53% | 4.63B | |
+17.40% | 4.18B | |
-23.98% | 3.81B | |
-25.83% | 2.8B | |
0.00% | 2B |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Medical Concepts, Inc. Revises Earnings Guidance for the Full-Year 2024